188 related articles for article (PubMed ID: 14624931)
21. Inhibition of the nuclear dihydrotestosterone receptor complex from rat ventral prostate by antiandrogens and stilboestrol.
Smith CB; Ghanadian R; Chisholm GD
Mol Cell Endocrinol; 1978; 10(1):13-20. PubMed ID: 75813
[No Abstract] [Full Text] [Related]
22. Steroidal antiandrogens and 5alpha-reductase inhibitors.
Bratoeff E; Ramírez E; Murillo E; Flores G; Cabeza M
Curr Med Chem; 1999 Dec; 6(12):1107-23. PubMed ID: 10519917
[TBL] [Abstract][Full Text] [Related]
23. Effects of two non-steroidal antiandrogens on testicular function in prepubertal rats.
Rulli SB; Gonzalez-Calvar SI; Campo S; Calandra RS
J Androl; 1995; 16(3):225-32. PubMed ID: 7559155
[TBL] [Abstract][Full Text] [Related]
24. Evidence for the regulation of prostatic oxytocin by gonadal steroids in the rat.
Jenkin L; Nicholson HD
J Androl; 1999; 20(1):80-7. PubMed ID: 10100477
[TBL] [Abstract][Full Text] [Related]
25. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
Simard J; Singh SM; Labrie F
Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
[TBL] [Abstract][Full Text] [Related]
26. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro.
Bologna M; Muzi P; Biordi L; Festuccia C; Vicentini C
Urology; 1995 Feb; 45(2):282-90. PubMed ID: 7855976
[TBL] [Abstract][Full Text] [Related]
27. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
[TBL] [Abstract][Full Text] [Related]
28. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
[TBL] [Abstract][Full Text] [Related]
29. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
30. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
[TBL] [Abstract][Full Text] [Related]
31. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats.
Tsukamoto S; Akaza H; Onozawa M; Shirai T; Ideyama Y
Cancer; 1998 Feb; 82(3):531-7. PubMed ID: 9452271
[TBL] [Abstract][Full Text] [Related]
32. [The effects of antiprostatic agents on the accessory sex organs of rats treated with adrenal androgens].
Imai K; Takahashi O; Watanabe K; Nakazawa Y; Nakata S; Yamanaka H
Hinyokika Kiyo; 1991 Dec; 37(12):1669-76. PubMed ID: 1785391
[TBL] [Abstract][Full Text] [Related]
33. Suppressive effects of the antiandrogen agent, chlormadinone acetate and the 5alpha-reductase inhibitor, dutasteride on prostate weight and intraprostatic androgen levels in rats.
Kobayashi H; Gotanda K; Shibata Y; Watanabe J; Nakano Y; Shinbo A; Suzuki K
Arzneimittelforschung; 2011; 61(9):515-20. PubMed ID: 22029228
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies.
Imperato-McGinley J; Sanchez RS; Spencer JR; Yee B; Vaughan ED
Endocrinology; 1992 Sep; 131(3):1149-56. PubMed ID: 1324152
[TBL] [Abstract][Full Text] [Related]
35. Sex-specific action of antiandrogens on androgen induced changes in hepatic microsomal 3 beta-hydroxysteroid dehydrogenase and 5 alpha-reductase activity in the rat.
Lax ER; Schriefers H
Acta Endocrinol (Copenh); 1981 Oct; 98(2):261-6. PubMed ID: 6457494
[TBL] [Abstract][Full Text] [Related]
36. Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.
Zaccheo T; Giudici D; di Salle E
Prostate; 1997 Feb; 30(2):85-91. PubMed ID: 9051146
[TBL] [Abstract][Full Text] [Related]
37. Treatment with antiandrogens induces an androgen-repressed gene in the rat ventral prostate.
Léger JG; Le Guellec R; Tenniswood MP
Prostate; 1988; 13(2):131-42. PubMed ID: 2459682
[TBL] [Abstract][Full Text] [Related]
38. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
George FW
Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of antiandrogens in the rat.
Burton S; Trachtenberg J
J Urol; 1986 Oct; 136(4):932-5. PubMed ID: 3761464
[TBL] [Abstract][Full Text] [Related]
40. Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity.
Luo S; Martel C; Chen C; Labrie C; Candas B; Singh SM; Labrie F
Urology; 1997 Dec; 50(6):913-9. PubMed ID: 9426723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
